NCT05441826 is a Phase 2 clinical trial of VB119 in Minimal Change Disease, sponsored by Tenet Medicines.

Who is sponsoring NCT05441826?

NCT05441826 is sponsored by Tenet Medicines.

What drugs are being tested in NCT05441826?

Interventions in NCT05441826: VB119.

What condition does NCT05441826 study?

NCT05441826 studies Minimal Change Disease, Focal Segmental Glomerulosclerosis.

Is NCT05441826 still recruiting?

NCT05441826 is currently terminated. Last updated 22 April 2024.

Last reviewed 2024-04-22 · How we verify

NCT05441826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Terminated Phase 2 Last updated 22 April 2024

What this trial tests

Phase 2 trial testing VB119 in Minimal Change Disease in 1 participant. Terminated before completion.

Timeline

3 May 2022

Primary endpoint
3 May 2023

12 October 2023

Quick facts

Lead sponsor	Tenet Medicines
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	3 May 2022
Primary completion	3 May 2023
Estimated completion	12 October 2023
Sites	1 location across United States

Drugs / interventions tested

VB119 — full drug profile →

Conditions studied

Minimal Change Disease — all drugs for Minimal Change Disease →
Focal Segmental Glomerulosclerosis — all drugs for Focal Segmental Glomerulosclerosis →

Sponsor

Tenet Medicines — full company profile →

Who can join

18 and older, any sex, with Minimal Change Disease or Focal Segmental Glomerulosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid therapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.
Mirioglu S, Daniel-Fischer L, Berke I, Ahmad SH, et al · · 2024 · cited 23× · PMID 38341276 · DOI 10.1093/ndt/gfae025
Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis.
de Cos M, Meliambro K, Campbell KN. · · 2023 · cited 22× · PMID 36644367 · DOI 10.1016/j.ekir.2022.10.004
Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury.
Zhu Y, Xu G. · · 2025 · cited 2× · PMID 39935575 · DOI 10.2147/dddt.s498457

Verify or expand the search:

Other trials of VB119

Trials testing the same drug.

NCT04652570 — Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy · Phase 1, PHASE2 · terminated

Other recruiting trials for Minimal Change Disease

Currently open trials in the same condition.

NCT05588063 — taVNS for FRNS in Children · NA · recruiting
NCT05583942 — A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) · NA · recruiting
NCT04571658 — NEPTUNE Match Study · NA · recruiting
NCT05505500 — Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. · recruiting
NCT05003986 — Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases · Phase 2 · recruiting

Other Tenet Medicines trials

Trials by the same sponsor.

NCT04652570 — Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05441826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tenet Medicines
Last refreshed: 22 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05441826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing